Posted on Wednesday 28 May 2014 by Ulster Business
Almac's has a busy year in 2013 opening a new facility at its Craigavon base. John McQuaid, Vice President of Almac's Technical Operations is pictured at the headquarters.
Pharmaceutical company Almac enjoyed a bumper year in 2013 with both profit and turnover heading higher, according to newly released results.
Chief executive Alan Armstrong said Almac is focused on its specialist area.
"Our long term objective is to be the leader in our chosen markets and following another successful year I'm pleased to report that we are showing sustained progress in reaching this goal.
"2013 was an exciting year for us with a major jobs boost in Craigavon as we completed a non-GMP drug development facility and expanded our manufacturing capabilities, announced a £13m investment in cancer research projects with Queen's University and signed a $9m deal with Genomic Health securing the rights to further develop and commericalise our breast cancer test."
Almac's business is focused on developing and manufacturing drugs for around 600 company around the world in the pharmaceutical and biosciences sector.
Steady growth over the last few years has seen it open operations in Pennsylvania in the US and also new facilities in Singapore and Japan.
Almac's new clinical trial secondary packaging facility in Singapore will better enable just-in-time supply management and support drug pooling strategies which further optimise the supply chain, minimise wastage and reduce costs.
Around 3,400 people now work for Almac globally, with over 2,000 based at its Craigavon headquarters.